Anti-TNF Therapy in the Swiss Inflammatory Bowel Disease G8 Cohort
Détails
ID Serval
serval:BIB_15022F8671C3
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Poster: résume de manière illustrée et sur une page unique les résultats d'un projet de recherche. Les résumés de poster doivent être entrés sous "Abstract" et non "Poster".
Collection
Publications
Institution
Titre
Anti-TNF Therapy in the Swiss Inflammatory Bowel Disease G8 Cohort
Titre de la conférence
Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition
Adresse
Interlaken, Switzerland, September 20-21, 2012
ISBN
1424-7860
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
2012
Volume
142
Série
Swiss Medical Weekly
Pages
12S
Langue
anglais
Résumé
Background: A nti-TNF d rugs (Infliximab (IFX), Adalimumab
(ADA), Certolizumab pegol (CZP)) are effective in inducing and
maintaining response a nd remission in i nflammatory bowel
disease (IBD). Insufficient response or side effects may lead to
a switch o f the anti-TNF d rug. W e aimed to e valuate the
frequency and reasons for anti-TNF switches.
Methods: Analysis of data from the Swiss Inflammatory Bowel
Disease Cohort (SIBDCS). Eighty percent of included patients
were recruited in hospitals and 20% from private practice.
Results: From 2,058 patients ( 1,172 with Crohn's disease
(CD), 842 with ulcerative colitis (UC) and 44 with indeterminate
colitis (IC)), 772 received at least one anti-TNF. Forty-eight % of
patients w ith CD, 23% with U C, a nd 30% with IC w ere ever
treated with an anti-TNF drug. There was no gender difference
with respect to the frequency of a nti-TNF treatment. A total of
584 patients (76%) were treated with one, 142 (18%) with two,
and 46 (6%) with three anti-TNF (of which 32 were female). A
total of 89% patients were treated with IFX, 28% ADA and 13%
with CZP. Overall response rate (defined as drop in CDAI >100
points) to anti-TNF was 50%, with best response rates for the
first used anti-TNF. Reasons t o switch t he anti-TNF w ere in
11% a primary non-response, in 38% a loss of response and in
36% anti-TNF s ide effects o r intolerance ( reasons for 15% of
treatment failures not documented).
Conclusion: A nti-TNF d rugs were used in h alf of the CD
patients a nd in o ne quarter of U C patients. Anti-TNF d rug
switch d ue to insufficient response a nd/or side effects w as
necessary in one quarter of IBD patients. IFX was mainly used
as first-line therapy. Best response rates were observed for the
first used anti-TNF. Following analyses will identify risk median
treatment duration as well as risk factors for anti-TNF switch.
(ADA), Certolizumab pegol (CZP)) are effective in inducing and
maintaining response a nd remission in i nflammatory bowel
disease (IBD). Insufficient response or side effects may lead to
a switch o f the anti-TNF d rug. W e aimed to e valuate the
frequency and reasons for anti-TNF switches.
Methods: Analysis of data from the Swiss Inflammatory Bowel
Disease Cohort (SIBDCS). Eighty percent of included patients
were recruited in hospitals and 20% from private practice.
Results: From 2,058 patients ( 1,172 with Crohn's disease
(CD), 842 with ulcerative colitis (UC) and 44 with indeterminate
colitis (IC)), 772 received at least one anti-TNF. Forty-eight % of
patients w ith CD, 23% with U C, a nd 30% with IC w ere ever
treated with an anti-TNF drug. There was no gender difference
with respect to the frequency of a nti-TNF treatment. A total of
584 patients (76%) were treated with one, 142 (18%) with two,
and 46 (6%) with three anti-TNF (of which 32 were female). A
total of 89% patients were treated with IFX, 28% ADA and 13%
with CZP. Overall response rate (defined as drop in CDAI >100
points) to anti-TNF was 50%, with best response rates for the
first used anti-TNF. Reasons t o switch t he anti-TNF w ere in
11% a primary non-response, in 38% a loss of response and in
36% anti-TNF s ide effects o r intolerance ( reasons for 15% of
treatment failures not documented).
Conclusion: A nti-TNF d rugs were used in h alf of the CD
patients a nd in o ne quarter of U C patients. Anti-TNF d rug
switch d ue to insufficient response a nd/or side effects w as
necessary in one quarter of IBD patients. IFX was mainly used
as first-line therapy. Best response rates were observed for the
first used anti-TNF. Following analyses will identify risk median
treatment duration as well as risk factors for anti-TNF switch.
Création de la notice
14/02/2013 14:37
Dernière modification de la notice
20/08/2019 13:43
Données d'usage
